|
Molecular properties generated using the CDK |
References |
1. Rueeger H et al.. (2012)
Bace-2 inhibitors for the treatment of metabolic disorders. Patent number: WO2012095521. Assignee: Novartis. Priority date: 03/01/2011. Publication date: 19/07/2012. |
2. Southan C. (2013)
BACE2 as a new diabetes target: a patent review (2010 - 2012). Expert Opin Ther Pat, 23 (5): 649-63. [PMID:23506624] |